Navigation Links
UT MD Anderson study finds women treated for breast cancer while pregnant have improved survival
Date:9/29/2010

HOUSTON - Long associated with a worse outcome, researchers at The University of Texas MD Anderson Cancer Center have discovered that women treated for breast cancer while pregnant, in fact, have improved disease-free survival and a trend for improved overall survival compared to non-pregnant women treated for the disease.

Jennifer Litton, M.D., assistant professor in MD Anderson's Department of Breast Medical Oncology, presented the findings in a poster discussion session at the 2010 Breast Cancer Symposium.

"Until now, older registry studies showed that breast cancer patients treated while pregnant had a worse outcome. However, in the past, these patients weren't always treated consistently with standard of care chemotherapy and often delayed their therapy until after delivery." said Litton, the study's first and corresponding author. "Given MD Anderson's experience in treating pregnant patients and our registry, we were able to look at these women treated by the same physicians, at the same institution, with the same standard of care."

In 1992, Richard Theriault, D.O., professor in the Department of Breast Medical Oncology, opened the first protocol examining a chemotherapeutic regimen for the management of these patients. He later published seminal studies proving that the regimen was safe for both pregnant mother and unborn child; it has since been adopted as the standard of care. MD Anderson has the oldest, active prospective registry in the world following the health of pregnant breast cancer patients and their children.

For the single institution, case-controlled study, Litton and her colleagues identified 75 women treated for breast cancer while pregnant. Using the institution's tumor registry and Department of Breast Medical Oncology database, the cases were compared to 150 non-pregnant breast cancer patients. Cases and controls were all treated at MD Anderson 1989 -2008, and were matched based on stage, age and year of diagnosis. Women who gave birth within one year of diagnosis were excluded from the comparison group.

All received the standard chemotherapy regimen - 5-fluorouracil, doxorubicin and cyclophosphamide (FAC); pregnant patients started therapy after completing their first trimester. Both groups received additional therapies as clinically indicated, with the pregnant women receiving those treatments after giving birth. The median follow-up was 4.16 years.

The researchers found a statistically significant five-year disease-free survival of 73.94 percent in pregnant women, compared to 55.75 percent in the non-pregnant patients. Although not statistically significant, overall survival was also higher in the cases than the controls: 77.42 percent and 71.86 percent, respectively.

"From this data set and our study, we are not sure why our pregnant breast cancer patients had better outcomes than those who were not," said Litton. "Is there something biological in the milieu of pregnancy that changes the response to chemotherapy? Or were these patients treated more aggressively?"

The reasons for the disease-free and overall survival discrepancy are still unknown, said Litton, and understanding their findings is of research priority.

"MD Anderson has a long history of being at the forefront of treating pregnant women for breast cancer, and, through our research, we've found it safe for both mother and child, and ultimately developed the standard of care," said Theriault, the study's senior author. "Now, when we are counseling breast cancer patients who are pregnant, we can say that they should have every expectation that they will do as well as our non-pregnant patients, and that they should start their treatment in the second or third trimester without delay."


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey
2. Peg Fields to receive MD Andersons highest nurse-oncologist honor
3. Anderson & Kriger Takes Donations to Families Affected by Baja's Easter Earthquake
4. NACDS' Anderson Says Retailers and Suppliers' “Health and Wellness Renaissance” is Creating a “Historic, Watershed Moment”
5. M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer
6. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
7. Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds
8. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
9. LodgeNet Healthcare Deploys Custom Education Solution for M. D. Anderson Cancer Center
10. David Anderson to discuss what model organisms can teach us about emotion
11. Anti-Inflammatory Helps Treat Bacterial Meningitis: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT MD Anderson study finds women treated for breast cancer while pregnant have improved survival
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology: